Antibodies

14 Sep 2020 FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
14 Sep 2020 Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
12 Sep 2020 Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
12 Sep 2020 Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate
11 Sep 2020 Fasenra met both co-primary endpoints of reduced nasal polyp size and blockage in the OSTRO Phase III trial for patients with chronic rhinosinusitis with nasal polyps
11 Sep 2020 Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
10 Sep 2020 Totient Partners with Ginkgo Bioworks to Apply Unique Discovery Platform to COVID-19 Antibody Efforts
10 Sep 2020 Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
10 Sep 2020 Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis
10 Sep 2020 Avillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody®, in chronic psoriasis
10 Sep 2020 Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
09 Sep 2020 Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
08 Sep 2020 Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody
08 Sep 2020 AVEO Oncology Regains Full Global Rights to Ficlatuzumab
07 Sep 2020 IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and Most Urgently for Covid-19
05 Sep 2020 AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
04 Sep 2020 Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
04 Sep 2020 Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
03 Sep 2020 Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China
02 Sep 2020 Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
02 Sep 2020 Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility
02 Sep 2020 Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020
02 Sep 2020 NeuClone Discloses Two Biosimilars Referencing Opdivo and Keytruda
01 Sep 2020 Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
01 Sep 2020 Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top